

**RECEIVED  
CENTRAL FAX CENTER**

**APR 17 2009**

PTO/SB/82 (01-06)

Approved for use through 12/31/2008. OMB 0651-0035

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>REVOCATION OF POWER OF ATTORNEY WITH NEW POWER OF ATTORNEY AND CHANGE OF CORRESPONDENCE ADDRESS</b>	Application Number	Please see Schedule A
	Filing Date	Please see Schedule A
	First Named Inventor	Please see Schedule A
	Art Unit	Please see Schedule A
	Examiner Name	Please see Schedule A
	Attorney Docket Number	105769-0001-GIP

I hereby revoke all previous powers of attorney given in the above-identified application.

☐ A Power of Attorney is submitted herewith.

OR

☒ I hereby appoint the practitioners associated with the Customer Number: 28120

☒ Please change the correspondence address for the above-identified application to:

☒ The address associated with  
Customer Number:

28120

OR

☐ Firm or  
Individual Name ROPES & GRAY LLP

Address			
City			
Country	State	Zip	
Telephone	Email		

I am the:

☐ Applicant/Inventor.

☒ Assignee of record of the entire interest. See 37 CFR 3.71.  
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)

**SIGNATURE of Applicant or Assignee of Record**

Signature

Name

John W. Gillard

Authorized Signer for Aegera Therapeutics Inc.

Date

2 April 2009

Telephone

514-288-4091

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.

☒ \*Total of 1 forms are submitted.

10766987\_1.DOC

RECEIVED  
CENTRAL FAX CENTER

APR 17 2009

PTO/SB/96 (10-07)

Approved for use through 10/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**STATEMENT UNDER 37 CFR 3.73(b)**Applicant/Patent Owner: See Schedule AApplication No./Patent No.: See Schedule A Filed/Issue Date: See Schedule AEntitled: See Schedule A

Aegera Therapeutics Inc., a Corporation  
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or  
 2. ☐ an assignee of less than the entire right, title and interest.  
 (The extent (by percentage) of its ownership interest is \_\_\_\_\_ %)

in the patent application/patent identified above by virtue of either:

- A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel See Attached Schedule A, Frame See Attached Schedule A, or for which a copy thereof is attached.

OR

- B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:


1. From: \_\_\_\_\_ To: \_\_\_\_\_  
 The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.  
 2. From: \_\_\_\_\_ To: \_\_\_\_\_  
 The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.  
 3. From: \_\_\_\_\_ To: \_\_\_\_\_  
 The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

- ☒ As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

  
 \_\_\_\_\_  
 Signature  
 John W. Gillard  
 Printed or Typed Name  
 \_\_\_\_\_  
 Authorized Signer for Aegera Therapeutics Inc.  
 Title

2 April 2009  
 \_\_\_\_\_  
 Date  
 514-288-4091  
 Telephone Number

RECEIVED  
CENTRAL FAX CENTER

APR 17 2009

Schedule A

Attorney Docket No.: 105769-0101-301	
Applicants: Jaquith et al.	
Application No.: 10/559,675	
Filed: December 6, 2005	
Title: ACYLATED AND NON-ACYLATED IMIDAZO [2,1-B]-1,3,4 - THIADIAZOLE-2-SULFONAMIDES AND USES THEREOF	
Patent No.:	Granted:
Assignee: Aegera Therapeutics Inc.	
Recordation Date:	Reel: 018494 Frame(s): 0068